First-Line Rucaparib Maintenance Provides Long-Term Benefits in Newly Diagnosed Ovarian Cancer
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.
A retrospective analysis showed that metastasectomy plus radical nephrectomy could improve survival in patients with metastatic non–clear cell RCC.
Answer each quiz question to better understand the patient’s journey and determine the correct diagnosis. Wolters Kluwer (“we” or “us”) wants to inform you about…
Tumor-associated macrophages (TAMs) are well known to fuel tumor evolution. Blériot et al. advocate for integrating the time dimension when conceptualizing macrophage diversity in pre-malignancy and cancer…
How do you express love to cancer patients in the ways that they’ll find the most meaningful? We went to senior social work counselor Vanessa…
R. Lor Randall, MD, FACS, detailed research into the relationship between guideline-concordant care and survival outcomes in patients with osteosarcoma in California.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Nazli Dizman, MD, discusses her research on adherence to the American Society of Clinical Oncology Language of Respect Guidelines among patients with renal cell carcinoma.
Phase 1 of the Acclaim-3 study evaluating quaratusugene ozeplasmid plus atezolizumab in patients with extensive-stage small cell lung cancer has enrolled and dosed its first…